HRS-9821 vs KIT2014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline
HRS-9821
Developed by GlaxoSmithKline and partners
NCT05622864 · Phase 1 · completed
The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Assess the incidence and severity of adverse events after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
KIT2014
Developed by Kither Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07668518 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRS-9821 | KIT2014 |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | —Not reported |
| SGRQ total, change | —Not reported | —Not reported |
| TDI focal score | —Not reported | —Not reported |
Moderate or severe exacerbations, annualised rate
- HRS-9821
- —Not reported
- KIT2014
- —Not reported
Trough FEV1, change
- HRS-9821
- —Not reported
- KIT2014
- —Not reported
SGRQ total, change
- HRS-9821
- —Not reported
- KIT2014
- —Not reported
TDI focal score
- HRS-9821
- —Not reported
- KIT2014
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-9821: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
KIT2014: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-9821's landscape · KIT2014's landscape